ArticleChemical biology & drug design2026
Probing Cinnamamides and Benzamides as Anthelmintics: Discovery of Potent Drug-Like Agents Against Angiostrongylus cantonensis.
Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Andrographolide as a Promising Diterpenoid Scaffold Against the Neurotropic NematodePharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Emergent helminthiases are increasingly impacting global health in both humans and animals, especially given the limited efficacy of existing drugs against these infections. Neuroangiostrongyliasis, an eosinophilic meningitis caused by Angiostrongylus cantonensis, currently lacks effective treatment, highlighting the need for novel anthelmintics. We previously identified cinnamoyl-benzylpiperazine, a simplified analogue of cinnarizine, as an effective anthelmintic agent against first (L1) and third-stage (L3) larvae of A. cantonensis in vitro. In the present work, structural modifications on the active prototype cinnamoyl-benzylpiperazine were performed, prioritizing the improvement of solubility and the provision of balanced physicochemical properties compatible with blood-brain barrier permeability, alongside anthelmintic activity. A set of 31 compounds divided into two series (I-cinnamoyl and II-benzoyl) was synthesized and tested against L1 and L3 larvae, yielding EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.